Literature DB >> 21553046

Should we screen for hereditary hemochromatosis in healthy Lebanese: a pilot study.

Rami A R Mahfouz1, Doja S Sarieddine, Khalil M Charafeddine, Rabab N Abdul Khalik, Najwa K Cortas, Rose T Daher.   

Abstract

Hereditary hemochromatosis (HHC) is a genetic disorder of iron metabolism characterized by abnormal accumulation of iron that may lead to organ damage and death. Diagnosis is usually based on various genetic and phenotypic criteria. The study goals were to perform mutation analysis for 18 different mutations associated with HHC in healthy Lebanese, determine their allele frequency, and compare iron-overload status in identified carriers versus those found to be wild-type for mutations analyzed. 116 healthy adults (59 males and 57 females) underwent DNA testing for 18 different HHC mutations, and biochemical testing for percent transferrin saturation (%TS) and ferritin. C282Y mutation was not detected. Only H63D mutation (rs1799945) was found with an overall carrier frequency of 25.8% (24.1% heterozygous and 1.7% homozygous). %TS and ferritin differed significantly between genders. %TS and ferritin were significantly higher in males with H63D mutation when compared to males with wild-type (P=0.001, 0.019; respectively); but not in females. The proportion of subjects with increased %TS and serum ferritin was not statistically different between those with H63D mutation and the wild-type in either gender. In addition, none of the subjects had concurrent increase in %TS and ferritin. In conclusion, the H63D carrier frequency in healthy Lebanese is comparable to other populations in the region, and it does not result in significant biochemical iron overload. Moreover, in the absence of the C282Y mutation, genetic screening for HHC is not recommended according to this preliminary study in healthy Lebanese.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553046     DOI: 10.1007/s11033-011-0795-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  27 in total

Review 1.  Review article: the genetic basis of haemochromatosis.

Authors:  W J H Griffiths
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

Review 2.  Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.

Authors:  Evelyn P Whitlock; Betsy A Garlitz; Emily L Harris; Tracy L Beil; Paula R Smith
Journal:  Ann Intern Med       Date:  2006-08-01       Impact factor: 25.391

3.  Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.

Authors:  P Harmatz; E Butensky; K Quirolo; R Williams; L Ferrell; T Moyer; D Golden; L Neumayr; E Vichinsky
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

4.  Mutations of the HFE gene among Turkish hereditary hemochromatosis patients.

Authors:  Halis Simsek; Yasemin H Balaban; Engin Yilmaz; Hale Sumer; Yahya Buyukasik; Cem Cengiz; Osman Ozcebe; Gulsen Hascelik; Gonca Tatar
Journal:  Ann Hematol       Date:  2005-05-04       Impact factor: 3.673

5.  Frequency of HFE mutations among Turkish blood donors according to transferrin saturation: genotype screening for hereditary hemochromatosis among voluntary blood donors in Turkey.

Authors:  Halis Simsek; Hale Sumer; Engin Yilmaz; Yasemin H Balaban; Osman Ozcebe; Gulsen Hascelik; Yahya Buyukask; Gonca Tatar
Journal:  J Clin Gastroenterol       Date:  2004-09       Impact factor: 3.062

6.  Definition of C282Y mutation in a hereditary hemochromatosis family from Turkey.

Authors:  Oya Yönal; Ozden Hatirnaz; Filiz Akyüz; Gupse Köroğlu; Uğur Ozbek; Kivanç Cefle; Zeynel Mungan
Journal:  Turk J Gastroenterol       Date:  2007-03       Impact factor: 1.852

7.  Screening for hemochromatosis by measuring ferritin levels: a more effective approach.

Authors:  Jill Waalen; Vincent J Felitti; Terri Gelbart; Ernest Beutler
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

Review 8.  Iron homeostasis: new players, newer insights.

Authors:  Eunice S Edison; Ashish Bajel; Mammen Chandy
Journal:  Eur J Haematol       Date:  2008-09-13       Impact factor: 2.997

9.  HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity.

Authors:  Lyle C Gurrin; Nadine A Bertalli; Gregory W Dalton; Nicholas J Osborne; Clare C Constantine; Christine E McLaren; Dallas R English; Dorota M Gertig; Martin B Delatycki; Amanda J Nicoll; Melissa C Southey; John L Hopper; Graham G Giles; Gregory J Anderson; John K Olynyk; Lawrie W Powell; Katrina J Allen
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

Review 10.  HFE-associated hereditary hemochromatosis.

Authors:  Jacob Alexander; Kris V Kowdley
Journal:  Genet Med       Date:  2009-05       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.